Akebia Therapeutics vs Anaptysbio
Akebia Therapeutics and Anaptysbio are similar in size: $236m and $235m of revenue in their latest fiscal years. Anaptysbio grew faster (157.0% against 47.5%). Akebia Therapeutics kept more of each dollar of sales as profit: a net margin of -2.3% against -5.6%.
| Latest fiscal year | Akebia TherapeuticsAKBA, 2025 | AnaptysbioANAB, 2025 |
|---|---|---|
| Revenue | $236m | $235m |
| Revenue growth | 47.5% | 157.0% |
| Net income | −$5.3m | −$13.2m |
| Operating margin | — | 96.7% |
| Net margin | -2.3% | -5.6% |
| Return on equity | — | -24.5% |
| Free cash flow | $67.7m | $19.6m |
| Cash | $185m | $138m |
| Total debt | $52.4m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $68.6m |
| Employees | 194 | 104 |
| Market value | $193m | $1.42bn |
| Price vs our value range | — | — |
| Moat score | 23 (Weak) | 13 (Weak) |
| Insider trades, 12 months | 1 buys, 16 sales | 0 buys, 42 sales |